Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) were up 1.2% on Thursday . The stock traded as high as $63.54 and last traded at $61.04. Approximately 418,250 shares traded hands during trading, an increase of 121% from the average daily volume of 189,291 shares. The stock had previously closed at $60.34.
Gemini Therapeutics Stock Performance
The company has a market cap of $2.64 billion, a P/E ratio of -61.04 and a beta of -0.12. The firm has a 50 day moving average price of $59.54 and a two-hundred day moving average price of $52.40.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Seagate Is Wall Street’s New Favorite AI Infrastructure Play
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 AI Infrastructure Stocks With Upside After the Summer Rally
- Which Wall Street Analysts are the Most Accurate?
- Can Advantage2 Help Overcome D-Wave’s Share Price Plateau?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
